Ge Healthcare Stock: An In-Depth Analysis for Serious Investors
GE HealthCare stock (ticker: GEHC) has traded as an independent public company since January 2023, when GE completed its three-way split into GE Aerospace, GE Vernova, and GE HealthCare. The ge healthcare stock represents a pure-play medical technology business generating approximately $20 billion in annual revenue, with its core franchise in imaging equipment (MRI, CT, ultrasound), patient monitoring, pharmaceutical diagnostics, and services. The forward P/E sits near 19x as of April 2026, which is a discount to larger medtech peers like Abbott and Becton Dickinson.
Understanding what that discount reflects, and whether it is justified, is the core question this analysis addresses.
Key Takeaways
- GEHC trades at a forward P/E near 19x and an EV/EBITDA near 13x, both below the medtech sector median of ~21x forward P/E and ~15x EV/EBITDA.
- Four business segments: Imaging (~53% of revenue), Ultrasound (~20%), Patient Care Solutions (~17%), and Pharmaceutical Diagnostics (~10%).
- The services and software component of GEHC's revenue, approximately 40% of total, provides a recurring revenue base with higher margins than hardware sales.
- Post-spin-off debt load (approximately $10 billion net debt) remains the primary overhang; interest coverage has improved from 4.2x at spin-off to approximately 6.1x as of Q4 2025.
- Adjusted EBITDA margins are expanding: from 15.1% in 2023 to approximately 17.8% in 2025, driven by pricing power in imaging and service contract renewals.
- The EV/Revenue multiple near 2.1x is below Abbott (3.4x) and Danaher (3.8x), suggesting GEHC is not priced for the full margin potential of its installed base.
GE HealthCare's Business Model After the Spin-Off
GEHC is a capital equipment and services business with a classic razor-and-blades dynamic. The company sells imaging systems (the razor) and then earns recurring revenue through service contracts, software subscriptions, and consumables (the blades) over the 10-to-20-year life of each installed unit.
This structure matters for valuation because the accounting does not fully reflect it. Hardware revenue is recognized at point of sale; service revenue is deferred and recognized over contract life. A quarter with heavy hardware shipments shows great revenue growth but compressed margins, because service margins run 10 to 15 points above hardware margins.
When you analyze ge healthcare stock, you need to separate these two revenue streams to understand the real economics. Approximately $8 billion of GEHC's annual revenue comes from service contracts and software, and that component is growing at roughly 8% annually.
Segment Revenue and Margin Breakdown
| Segment | 2025 Revenue (Est.) | YoY Growth | Adj. EBIT Margin |
|---|---|---|---|
| Imaging | ~$10.8B | +6.2% | ~19.4% |
| Ultrasound | ~$4.1B | +8.1% | ~22.8% |
| Patient Care Solutions | ~$3.5B | +3.4% | ~12.1% |
| Pharmaceutical Diagnostics | ~$2.0B | +11.8% | ~26.3% |
| Total | ~$20.4B | +6.5% | ~18.1% |
The Pharmaceutical Diagnostics segment is the highest-margin business and the fastest-growing. GEHC's contrast agents and radiopharmaceuticals are used in PET and CT scans globally, and the segment benefits from near-monopoly positioning in several specific diagnostic tracers. This segment alone justifies roughly $4 to $5 per share of the stock's current value on a standalone basis.
Patient Care Solutions is the weakest segment by both margin and growth. It includes patient monitoring hardware and ventilators, categories where GEHC faces direct competition from Philips and Mindray at lower price points.
Forward P/E Analysis: What 19x Prices In
A forward P/E of 19x for ge healthcare stock prices in approximately 9% annual EPS growth over the next three years. That is below GEHC's own consensus estimate of 11 to 13% EPS CAGR through 2028, which is driven by:
- Margin expansion from the post-spin-off cost-reduction program (GE HealthCare targets $300 million in structural savings by end of 2026).
- Mix shift toward higher-margin services and Pharmaceutical Diagnostics.
- Volume recovery in China, where hospital capital spending on imaging equipment was below trend in 2023 and 2024 due to an anti-corruption campaign in the healthcare sector.
If GEHC delivers 12% EPS growth and the forward P/E re-rates from 19x to 22x (the sector median), the stock has roughly 30% upside from current levels. That is the bull case. The bear case is that China volume recovery stalls and margin expansion slows, holding the P/E flat while EPS grows at 7 to 8%.
EV/EBITDA: Why This Multiple Matters More for GEHC
Because GEHC carries approximately $10 billion in net debt from the spin-off, the EV/EBITDA multiple is more informative than P/E for comparing it to peers.
At an EV/EBITDA near 13x, GEHC trades below Siemens Healthineers at approximately 16x and Philips at approximately 14x. The discount is partly warranted (GEHC has higher use) and partly a function of spin-off fatigue, where post-spin stocks are often orphaned by the index funds that owned the parent.
As GEHC pays down debt and earns inclusion in more healthcare indexes, the discount to peers should compress. The company has committed to reducing net leverage from approximately 2.3x EBITDA to below 1.5x by end of 2027 through a combination of free cash flow and selective asset sales.
EV/Revenue: Mapping the Margin Expansion Story
At an EV/Revenue multiple near 2.1x, ge healthcare stock implies an EBITDA margin of approximately 17 to 18% at steady state, which is roughly where GEHC is now. This means the market is pricing in very little margin expansion beyond the current trajectory.
Beckett Pharmacecuticals comparison is instructive. For context, Abbott trades at 3.4x EV/Revenue and a 24% EBITDA margin. If GEHC expands margins to 21% over four years (roughly in line with management guidance), the stock should re-rate toward 2.7 to 2.9x EV/Revenue. On current revenue that implies 30 to 40% stock appreciation before any revenue growth.
Use the ValueMarkers screener to track GEHC's EV/Revenue, EV/EBITDA, and forward P/E in real time alongside 120 other indicators, including the VMCI Score which weights Value (35%), Quality (30%), Integrity (15%), Growth (12%), and Risk (8%).
Key Risks to the GEHC Thesis
Three risks are worth quantifying, not just naming.
First, China exposure. GEHC generates approximately 13% of total revenue in China. A 20% volume decline in China (possible if hospital spending remains suppressed) reduces total revenue by 2.6% and EPS by approximately $0.35, or about 3.5% of the current consensus EPS estimate.
Second, tariff risk. GEHC manufactures in the U.S., China, Germany, and Finland. A 25% tariff on Chinese-manufactured components imported to the U.S. would increase cost of goods sold by an estimated $180 to $220 million annually, or approximately 1.1% of revenue. This risk is partially offset by supply chain diversification underway since 2023.
Third, interest expense drag. With $10 billion in net debt at an average interest rate near 4.3%, GEHC pays approximately $430 million annually in interest. Every 50 basis point increase in refinancing costs adds roughly $50 million to annual interest expense, reducing EPS by approximately $0.13.
How GEHC Compares to Johnson and Johnson and Abbott
Comparing ge healthcare stock to two established healthcare benchmarks shows both the discount and what that discount is compensating for.
| Company | Forward P/E | EV/EBITDA | EV/Revenue | Net Debt/EBITDA | Dividend Yield |
|---|---|---|---|---|---|
| GE HealthCare (GEHC) | ~19.0x | ~13.2x | ~2.1x | ~2.3x | ~0.3% |
| Johnson & Johnson (JNJ) | ~14.8x | ~12.4x | ~4.1x | ~0.4x | ~3.1% |
| Abbott Laboratories (ABT) | ~24.1x | ~18.6x | ~3.4x | ~0.9x | ~1.8% |
| Medtronic (MDT) | ~15.2x | ~12.1x | ~2.8x | ~1.8x | ~3.4% |
GEHC's premium to JNJ and Medtronic on forward P/E is entirely a function of its higher expected earnings growth. Its discount to Abbott reflects both use and Abbott's superior software and diagnostics business mix.
JNJ's 3.1% dividend yield makes it the income choice among these names; GEHC's 0.3% yield confirms that GEHC is a growth-and-revaluation story, not an income story.
Further reading: SEC EDGAR · FRED Economic Data
Why GEHC stock analysis Matters
This section anchors the discussion on GEHC stock analysis. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply GEHC stock analysis in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for GEHC stock analysis
See the main discussion of GEHC stock analysis in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using GEHC stock analysis alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for GEHC stock analysis
See the main discussion of GEHC stock analysis in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using GEHC stock analysis alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Forward Pe — Glossary entry for Forward Pe
- Enterprise Value to Revenue (EV/Revenue) — Enterprise Value to Revenue is the metric used to how cheaply a stock trades relative to its fundamentals
- Enterprise Value to EBITDA (EV/EBITDA) — Enterprise Value to EBITDA is the metric used to how cheaply a stock trades relative to its fundamentals
- Unitedhealth Stock Analysis Is Unh Stock A Smart Investment — related ValueMarkers analysis
- Jnj Stock Analysis Is Johnson And Johnson A Buy — related ValueMarkers analysis
- Sharesight Dividend Calculator — related ValueMarkers analysis
Frequently Asked Questions
what happens if the stock market crashes
If the stock market crashes, GE HealthCare stock would likely fall in line with the broader market initially, but the fundamental business would remain intact. Hospitals do not cancel equipment service contracts during recessions; capital expenditure on new imaging systems does slow, which would pressure GEHC's hardware revenue. In the 2020 pandemic crash, GE Healthcare (while still part of GE) saw equipment order delays of roughly one quarter before recovering. The services revenue base provides a floor.
what time does the stock market open
The U.S. stock market opens at 9:30 a.m. Eastern Time on weekdays, excluding market holidays. GEHC is listed on the Nasdaq, which observes the same 9:30 a.m. open. Pre-market trading begins at 4:00 a.m. Eastern through most brokerages, though GEHC's pre-market volume is thin outside of earnings announcement days.
are stock markets closed today
U.S. stock markets are closed on major federal holidays. GEHC, as a Nasdaq-listed stock, follows the standard NYSE and Nasdaq holiday calendar, which includes New Year's Day, Martin Luther King Jr. Day, Presidents' Day, Good Friday, Memorial Day, Juneteenth, Independence Day, Labor Day, Thanksgiving Day, and Christmas Day. Check the official Nasdaq calendar at nasdaq.com for exact dates each year.
what time does the stock market close
The regular U.S. trading session closes at 4:00 p.m. Eastern Time. GEHC typically reports quarterly earnings before the market open, so the first 30 minutes of the regular session on earnings days tend to have elevated volume and wider-than-normal bid-ask spreads.
when does the stock market open
The stock market opens at 9:30 a.m. Eastern Time Monday through Friday. If you are considering a position in ge healthcare stock ahead of an earnings release or a major medical conference (like RSNA in November or the J.P. Morgan Healthcare Conference in January), be aware that management guidance and product announcements at those events can move the stock before the regular session opens.
why is the stock market down today
Broad market declines affect GEHC like any other large-cap stock. However, sector-specific catalysts move GEHC more than macro news: CMS reimbursement changes for imaging procedures, FDA approvals or rejections for GEHC's new diagnostic products, and earnings reports from medtech peers like Siemens Healthineers or Philips that signal demand trends. If GEHC is down sharply on a day when the broader market is flat, the cause is almost always sector-specific.
Screen GE HealthCare against 120 fundamental indicators in the ValueMarkers screener to see how its VMCI score compares to peers across the medtech sector.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.